Thursday, January 26, 2017

BRIEF-Boehringer Ingelheim says jardiance becomes first type 2 diabetes medicine in EU to include cardiovascular death reduction data in label

* Boehringer ingelheim- jardiance (empagliflozin) becomes

first type 2 diabetes medicine in eu to include cardiovascular

death reduction data in label

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)